NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 67 filers reported holding NURIX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $8,579,000 | -40.6% | 677,143 | -34.3% | 2.31% | -42.8% |
| Q1 2022 | $14,441,000 | -58.6% | 1,030,798 | -14.5% | 4.04% | -43.7% |
| Q4 2021 | $34,908,000 | -3.4% | 1,205,798 | 0.0% | 7.18% | +35.0% |
| Q3 2021 | $36,126,000 | +12.9% | 1,205,798 | 0.0% | 5.32% | +23.0% |
| Q2 2021 | $31,990,000 | -16.9% | 1,205,798 | -2.6% | 4.32% | -6.2% |
| Q1 2021 | $38,504,000 | -50.1% | 1,238,456 | -47.3% | 4.61% | -45.0% |
| Q4 2020 | $77,196,000 | -5.8% | 2,347,804 | -0.0% | 8.38% | -54.6% |
| Q3 2020 | $81,969,000 | – | 2,348,014 | – | 18.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,422,549 | $90,800,000 | 15.85% |
| Ponoi II Management, LLC | 686,274 | $18,207,000 | 14.76% |
| Ponoi Management, LLC | 686,274 | $18,207,000 | 10.12% |
| Foresite Capital Management V, LLC | 451,522 | $11,979,000 | 4.71% |
| Foresite Capital Management IV, LLC | 1,205,798 | $31,990,000 | 4.32% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $34,073,000 | 2.23% |
| EcoR1 Capital, LLC | 1,967,950 | $52,210,000 | 1.95% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $15,155,000 | 1.93% |
| DAFNA Capital Management LLC | 306,320 | $8,127,000 | 1.70% |
| Euclidean Capital LLC | 154,426 | $4,097,000 | 1.33% |